Prevention of hematomas in the induction of injection cosmetology interventions

Cover Page

Abstract


The aim of the study was to assess the preventive efficacy of using topical brimonidine tartrate in individuals who underwent cosmetic cosmetology injections in terms of reducing the risk of skin hematoma formation at injection sites.

Materials and methods. The study included 296 patients; the average age of patients in the study was 36.3 ± 7.4 years. The criterion for the inclusion of patients in the study was either the presence of indications for the use of botulinum toxin type A drugs, or fillers. Patients were divided into groups of preventive use of topical brimonidine tartrate and a control group. The evaluation was carried out to achieve the end for patients — the onset of an episode of hemorrhagic complication of the injection procedure.

Results and conclusions. The study demonstrated a reduction in the risk of hemorrhagic complications in patients who underwent contour plastic with previous preventive prescription of topical brimonidine tartrate.


About the authors

M. V. Zhuchkov

Regional Clinical Skin and Venereal Disease Dispensary

Author for correspondence.
Email: misha.juchkov@gmail.com

Russian Federation

Cand. Sci. (Med.), Chief Dermatovenereologist and Cosmetologist of the Ministry of Health of the Ryazan Region, Deputy Chief Physician,

Sportivnaya str., 9, Ryazan, 390046

E. E. Bolshakova

Regional Clinical Skin and Venereal Disease Dispensary

Email: fake@neicon.ru

Russian Federation

Head Doctor, Chairman of the Ryazan Regional Branch “RODVK”,

Sportivnaya str., 9, Ryazan, 390046

D. B. Sonin

Regional Clinical Skin and Venereal Disease Dispensary

Email: fake@neicon.ru

Russian Federation

Cand. Sci. (Med.), Deputy Head Doctor of the Regional Clinical Skin and Venereal Diseases Clinic of the Regional Clinical Hospital,

Sportivnaya str., 9, Ryazan, 390046

U. V. Zhuchkova

City Clinical Emergency Hospital
Dzerzhinskogo str., 11, Ryazan, 390013

Email: fake@neicon.ru

Russian Federation

Cand. Sci. (Med.), surgeon of the Regional Clinical Hospital Emergency Clinical Hospital

Dzerzhinskogo str., 11, Ryazan, 390013

References

  1. Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981;72(4):413–415.
  2. Gómez-Aguayo F., Paczka J. A., Leñero-Córdova R., JiménezRomán J., Davila-Villarreal J., Hartleben C. et al. A Phase III Randomized Clinical Trial of a 0.5 % Timolol + 0.2 % Brimonidine + 2.0 % Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5 % Timolol + 0.2 % Brimonidine + 2.0 % Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):145–146.
  3. Fowler J., Jarratt M., Moore A., Meadows K., Pollack A., Steinhoff M. et al. Once-daily topical brimonidine tartrate gel 0,5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633–641.
  4. Gold L. S., Papp K., Lynde C., Lain E., Gooderham M., Johnson S. et al. Treatment of Rosacea with Concomitant Use of Topical Ivermectin 1 % Cream and Brimonidine 0.33 % Gel: A Randomized, Vehiclecontrolled Study. J Drugs Dermatol. 2017;16(9):909–916.
  5. Klein A. W. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20(2):109–120.
  6. Lowe P. L., Patnaik R., Lowe N. J. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg. 2005;31(12):1651–1654.
  7. Wollina U., Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141–145.

Statistics

Views

Abstract - 860

PDF (Russian) - 260

PlumX

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Dimensions


Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies